非小细胞肺癌免疫治疗研究进展.docx
上传者:森森
2022-06-18 10:59:50上传
DOCX文件
17 KB
非小细胞肺癌免疫治疗研究进展
Medical Diagnosis 医学诊断, 2022, 6(1), 15-20
Published Online March 2022 in Hans. https://www.sodocs.net/doc/4b2596740.html /journal/md
https://www.sodocs.net/doc/4b2596740.html /10.12677/md.2022.61014
Advances in Immune Therapy for Non Small Cell Lung Cancer
Xinhui Jiang1, Weizhen Shou2
1Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Baoshan Branch,
Shanghai
2Longhua Hospital Affiliated to Shanghai University of Chinese Medicine, Shanghai
Received: Feb. 24th, 2022; accepted: Mar. 15th, 2022; published: Mar. 18th, 2022
Copyright ? 2022 by authors and Hans Publishers Inc.
This work is licensed under the Creative Commons Attribution International License (CC BY).
https://www.sodocs.net/doc/4b2596740.html /licenses/by/4.0/
Abstract
At present, lung cancer has become the leading cause of death in various types of cancer, the inci-dence and mortality rate is rising. In recent years, although non small cell lung cancer patients survival rate prolongs the combination therapy with chemotherapy, patients and the overall 5- year survival rate is very low, and due to the additional damage of radiotherapy and chemothera-py, the patient’s quality of life a
Medical Diagnosis 医学诊断, 2022, 6(1), 15-20
Published Online March 2022 in Hans. https://www.sodocs.net/doc/4b2596740.html /journal/md
https://www.sodocs.net/doc/4b2596740.html /10.12677/md.2022.61014
Advances in Immune Therapy for Non Small Cell Lung Cancer
Xinhui Jiang1, Weizhen Shou2
1Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Baoshan Branch,
Shanghai
2Longhua Hospital Affiliated to Shanghai University of Chinese Medicine, Shanghai
Received: Feb. 24th, 2022; accepted: Mar. 15th, 2022; published: Mar. 18th, 2022
Copyright ? 2022 by authors and Hans Publishers Inc.
This work is licensed under the Creative Commons Attribution International License (CC BY).
https://www.sodocs.net/doc/4b2596740.html /licenses/by/4.0/
Abstract
At present, lung cancer has become the leading cause of death in various types of cancer, the inci-dence and mortality rate is rising. In recent years, although non small cell lung cancer patients survival rate prolongs the combination therapy with chemotherapy, patients and the overall 5- year survival rate is very low, and due to the additional damage of radiotherapy and chemothera-py, the patient’s quality of life a
非小细胞肺癌免疫治疗研究进展